How many clinical-trial readouts are scheduled for October 2026?

pdufa.bio currently tracks 41 clinical-trial readouts with dates in October 2026, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Decisions Readouts Run-up Stocks

Drug Index Conferences Advisory Committees Screener Research API SLS tracker Account

Pro

Home › Readouts › October 2026

October 2026 clinical-trial readouts

Updated August 7, 2026·next FDA decision on the calendar

trial-readout estimates for October 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← September 2026 November 2026 →

25 readouts

OGN · Oct 2026 (est.)

150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5: Plaque Psoriasis

Awaiting data

PFE · Oct 2026 (est.)

Palbociclib: Metastatic Renal Cell Carcinoma

ABOS · Oct 2026 (est.)

sabirnetug: Alzheimer Disease

Awaiting dataupdated 8mo ago

MIRM · Oct 2026 (est.)

Maralixibat, Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

Awaiting data

CLDX · Oct 2026 (est.)

Barzolvolimab: Chronic Spontaneous Urticaria

Awaiting data

EYPT · Oct 2026 (est.)

EYP-1901: Wet Age Related Macular Degeneration

Awaiting data

HUMA · Oct 2026 (est.)

Human Acellular Vessel: End Stage Renal Disease (ESRD)

Awaiting data

IMVT · Oct 2026 (est.)

IMVT-1402: Subacute Cutaneous Lupus Erythematosus

Awaiting data

TECX · Oct 2026 (est.)

TX000045- Dose A: Pulmonary Hypertension

Awaiting data

SLDB · Oct 2026 (est.)

SGT-003: Duchenne Muscular Dystrophy

Awaiting data

INCY · Oct 2026 (est.)

Povorcitinib: Prurigo Nodularis

BIIB · Oct 2026 (est.)

Litifilimab: Subacute Cutaneous Lupus Erythematosus

CSLLY · Oct 2026 (est.)

Recombinant Single-Chain Factor Viii: Congenital Hemophilia A

Awaiting data

SNY · Oct 2026 (est.)

Venglustat: Gaucher Disease Type 1

MRK · Oct 2026 (est.)

Pembrolizumab: Metastatic Uveal Melanoma

INBX · Oct 2026 (est.)

INBRX-106: Solid Tumor

Awaiting dataupdated 6mo ago

VTRS · Oct 2026 (est.)

Cenerimod: Lupus Erythematosus, Systemic

JSPR · Oct 2026 (est.)

Briquilimab: Chronic Spontaneous Urticaria

Awaiting dataupdated 5mo ago

MRK · Oct 2026 (est.)

IMG-7289: Essential Thrombocythemia

RCUS · Oct 2026 (est.)

Zimberelimab: Non Small Cell Lung Cancer

Awaiting data

RYTM · Oct 2026 (est.)

Setmelanotide: Prader-Willi Syndrome

Awaiting dataupdated 4mo ago

SRPT · Oct 2026 (est.)

Eteplirsen: Muscular Dystrophy, Duchenne

Awaiting dataupdated 4mo ago

SYRE · Oct 2026 (est.)

SPY001: Rheumatoid Arthritis

Awaiting data

ANNX · Oct 2026 (est.)

Tanruprubart: Geographic Atrophy

Awaiting data

IMMP · Oct 2026 (est.)

eftilagimod alfa: Breast Carcinoma

Awaiting dataupdated 19mo ago

Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).